A Cure for Investor Skepticism

Regenerative medicine could reshape our world... and with investor confidence growing, it's becoming ever closer to reality.

 |  Transcript [PDF]

Regenerative medicine has the potential to provide actual cures for patients, instead of being limited to treating symptoms. But when new markets like this are emerging, it can be difficult to gain traction with investors.

“It’s a long process, particularly in the therapeutic area where a lot needs to be invested in those early stages when ideas just aren’t proven,” says Mitchel Sivilotti, Chief Operating Officer at the Centre for Commercialization of Regenerative Medicine (CCRM).

CCRM is a leader in helping bring together the whole ecosystem of players needed to develop and commercialize regenerative medicine.

“An important reason why CCRM exists is because it’s very difficult for companies to get from that initial idea to the clinic, to the patient, to an organization that is creating revenue to grow an economy,” adds Sivilotti.

To help those ideas along, CCRM is there for every stage of the process.

Starting with academics and graduate students who are making important discoveries, CCRM provides the training they need to get their ideas off the ground, from a better understanding of intellectual property and patents, to knowing what to expect in the beginning stages of commercialization. Many graduate students who work with CCRM wind up being the future leaders of the spin off companies that they build together.

Then there’s the commercialization expertise needed at later stages. CCRM helps secure financial backing, but also guides further scientific work. They have laboratory facilities that help fill in the rest of the scientific gaps, resolve any unknowns in scaling up a manufacturing process, and prepare new treatment options for clinical trials.

While these are still early days for the regenerative medicine field, Sivilotti says it’s a good sign that regenerative medicine is starting to reach the market. For instance, a personalized T-cell immunotherapy developed at Novartis to treat leukemia was recently approved for patients in the United States, a trend that will likely spread into Canada soon.

“These are signs of the industry reaching a level of maturity where investors are becoming more confident,” says Sivilotti. “There’s going to be more investment in these companies, and it’s an industry that will start growing even faster than it already is.”

‹ Previous post
Next post ›

Prior to joining CCRM, Sivilotti led operations, manufacturing, development, and commercial departments at Cesca Therapeutics, Inc. (Nasdaq: KOOL), located in Rancho Cordova, California. While at Cesca, Mitch managed a global employee base (U.S., EU, India, China) involved in all aspects of regenerative medicine-based software, controlled electromechanical devices and companion disposables for therapeutic use in Intraoperative Orthopedics (Spine & Non-Unions) & Hematology/Oncology Markets (BMT, Cord Blood). Cesca Therapeutics was the result of a $80M USD merger between Thermogenesis Corp. and TotipotentRX Corporation, which Sivilotti co-founded in 2007 in Los Angeles, California. 

While at TotipotentRX, Sivilotti served as Chief Executive Officer and Director from 2008 to 2012 and as President and Director from 2012 to 2013. From 2003 to 2007, he served in various key technical and business leadership roles at Pall Corporation (now Danaher Corporation NYSE:DHR), completing his tenure as Global Marketing Manager, Regenerative Medicine. Sivilotti holds a graduate degree in Cellular and Molecular Biology from the Université Laval (Quebec, Canada) and a graduate degree in Finance from Queen’s University (Kingston, Canada). 


Research2Reality is a groundbreaking initiative that shines a spotlight on world-class scientists engaged in innovative and leading edge research in Canada. Our video series is continually updated to celebrate the success of researchers who are establishing the new frontiers of science and to share the impact of their discoveries with the public.